argenx SE (ARGX): Price and Financial Metrics


argenx SE (ARGX): $323.10

7.13 (+2.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARGX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARGX POWR Grades


  • Value is the dimension where ARGX ranks best; there it ranks ahead of 57.67% of US stocks.
  • ARGX's strongest trending metric is Sentiment; it's been moving down over the last 179 days.
  • ARGX's current lowest rank is in the Growth metric (where it is better than 2.81% of US stocks).

ARGX Stock Summary

  • For ARGX, its debt to operating expenses ratio is greater than that reported by merely 6.02% of US equities we're observing.
  • With a price/sales ratio of 29.05, Argenx Se has a higher such ratio than 94.48% of stocks in our set.
  • Revenue growth over the past 12 months for Argenx Se comes in at 854.97%, a number that bests 98.84% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Argenx Se, a group of peers worth examining would be AKTS, CUE, VRNA, ACRS, and IMTX.
  • Visit ARGX's SEC page to see the company's official filings. To visit the company's web site, go to www.argenx.com.

ARGX Stock Price Chart Interactive Chart >

Price chart for ARGX

ARGX Price/Volume Stats

Current price $323.10 52-week high $356.78
Prev. close $315.97 52-week low $249.50
Day low $313.63 Volume 318,700
Day high $323.67 Avg. volume 270,542
50-day MA $311.01 Dividend yield N/A
200-day MA $304.69 Market Cap 17.32B

argenx SE (ARGX) Company Bio


arGEN-X N.V., a clinical-stage biopharmaceutical company, focuses on creating and developing therapeutic antibodies for the treatment of cancer and autoimmune diseases. The company was founded in 2008 and is based in Breda, Netherlands.


ARGX Latest News Stream


Event/Time News Detail
Loading, please wait...

ARGX Latest Social Stream


Loading social stream, please wait...

View Full ARGX Social Stream

Latest ARGX News From Around the Web

Below are the latest news stories about Argenx Se that investors may wish to consider to help them evaluate ARGX as an investment opportunity.

argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022

February 24, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 3, 2022 at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website a

Yahoo | February 24, 2022

argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors.

Yahoo | February 10, 2022

Garrison Bradford & Associates Inc Buys argenx SE, Apple Inc, Brookfield Asset Management ...

New York, NY, based Investment company Garrison Bradford & Associates Inc (Current Portfolio) buys argenx SE, Apple Inc, Brookfield Asset Management Inc, Walmart Inc, sells Vanguard Short-Term Inflation-Protected Securities, PIMCO Dynamic Credit & Mortgage Income Fund, Essent Group, Aberdeen Asia-pacific Income Fund Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Garrison Bradford & Associates Inc.

Yahoo | February 1, 2022

Argenx Se (ARGX) Receives a Buy from JMP Securities

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Argenx Se (ARGX – Research Report), with a price target of $418.00. The company's shares closed last Thursday at $287.18. According to TipRanks.com, Butler is a 1-star analyst with an average return of -2.1% and a 37.2% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals. Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $380.69, which is a 34.1% upside from current levels.

Howard Kim on TipRanks | January 20, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agile Therapeutics (AGRX), Argenx Se (ARGX) and Liminal BioSciences (LMNL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agile Therapeutics (AGRX – Research Report), Argenx Se (ARGX – Research Report) and Liminal BioSciences (LMNL – Research Report). Agile Therapeutics (AGRX) In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $2.50. The company's shares closed last Wednesday at $0.34, close to its 52-week low of $0.34. According to TipRanks.

Catie Powers on TipRanks | January 20, 2022

Read More 'ARGX' Stories Here

ARGX Price Returns

1-mo 12.21%
3-mo 12.84%
6-mo 16.93%
1-year 15.81%
3-year 152.98%
5-year 1,503.47%
YTD -7.74%
2021 19.08%
2020 83.21%
2019 67.09%
2018 52.15%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7705 seconds.